Addressing lingering safety issues for I-O product candidates in development

IMMUNO-ONCOLOGY INSIGHTS

Addressing lingering safety issues for I-O product candidates in development

December 2020
Addressing lingering safety issues for I-O product candidates in development
Download PDF

Commentary

Necessity for next-generation quality assessment of CAR T cell manufacturing and advanced therapy guidance

Necessity for next-generation quality assessment of CAR T cell manufacturing and advanced therapy guidance

B Seliger, K Reiche, C Massa et al.
15 December 2020
Read
Model-based dose escalation designs used in early-phase 1 trials to assess safety and tolerability of immuno-oncology therapies

Model-based dose escalation designs used in early-phase 1 trials to assess safety and tolerability of immuno-oncology therapies

Céline Adessi, Francesca Michielin
15 December 2020
Read
The rise of next-generation T-cell engagers with better safety and efficacy

The rise of next-generation T-cell engagers with better safety and efficacy

Omid Vafa
8 December 2020
Read

Interview

T cell immunotherapy: addressing toxicity issues in a rapidly commercializing field

T cell immunotherapy: addressing toxicity issues in a rapidly commercializing field

John Rossi
15 January 2021
Read
Future pathways towards improving clinical safety and efficacy of immunotherapy agents in melanoma

Future pathways towards improving clinical safety and efficacy of immunotherapy agents in melanoma

Paolo A Ascierto
8 December 2020
Read

Short Communication

Early use of tocilizumab and lead-in dose to mitigate flotetuzumab associated infusion-related reaction/cytokine release reaction in patients with relapsed or refractory acute myeloid leukemia

Early use of tocilizumab and lead-in dose to mitigate flotetuzumab associated infusion-related reaction/cytokine release reaction in patients with relapsed or refractory acute myeloid leukemia

K Jacobs, O Bakkacha, P Patel et al.
9 December 2020
Read